Patient Input Impact on Drug Commercialization
Pre- and post-product launch advocacy relations activities historically consist of identifying appropriate ways industry and patient groups work together to address their shared interests, including use of a medication. In general, unmet needs fall into these categories:

Disease awareness. What do patients and providers know about a particular disease or condition? Patients with less well-known diseases and conditions often are the true experts. Even their doctors learn from them. Those with more common diseases face other challenges, including stigma. Lung cancer is an excellent example. Lung cancer patients may not be offered support and treatment even when new effective treatments are available because they are blamed for their illness.
Improvement in treatment. How well does the new product treat what patients care about? How does a drug’s efficacy impact treatment decision making and patient choice? What tools and resources do patients need to have informed conversations with their HCPs?
Activating patients. What shapes the ability and willingness of patients to embrace innovation, participate in treatment decision making, and adhere to treatment regimens? Increasingly, patients embrace the chance to take responsibility for choosing their treatments and managing their illness. Still, others are not ready and willing; how can advocacy and industry collaborate to help?
Channels and messaging for reaching patients. How and where do patients receive information? What is required to help them make informed choices and how can underserved populations be included? With so much noise online, how do we ensure patients receive credible information?
Access barriers. If patients can’t afford a medication, what systems must be in place to ensure appropriate patients are able to access it?
https://www.pm360online.com/can-advocacy-relations-benefit-l...